Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

yf_tkr_RARE · 2026-08-25

$RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the first approved treatment designed to address the disorder’s underlying cause. It will carry a U.S. list price of approximately […]

Read the original at yf_tkr_RARE ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.